The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and outcome of patients with MYD88 wild-type Waldenström Macroglobulinemia.
 
Saurabh Zanwar
No Relationships to Disclose
 
Jithma P. Abeykoon
No Relationships to Disclose
 
Stephen M. Ansell
Honoraria - Research to Practice; WebMD
Research Funding - Affimed Therapeutics (Inst); AI Therapeutics (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Regeneron (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Jonas Paludo
Research Funding - Celgene (Inst)
 
Morie A. Gertz
Honoraria - Abbvie; Akcea Therapeutics; Amgen; Apellis Pharmaceuticals; Celgene; Med Learning Group; Prothena; Research to Practice
Consulting or Advisory Role - Prothena
Travel, Accommodations, Expenses - Celgene; Novartis; Prothena
 
Carrie A. Thompson
No Relationships to Disclose
 
Rebecca L. King
No Relationships to Disclose
 
Rong He
No Relationships to Disclose
 
Nora N Benanni
Consulting or Advisory Role - Adicet Bio (Inst); Purdue Pharma (Inst); Seagen (Inst); Verastem (Inst)
Research Funding - Kite, a Gilead company (Inst)
 
Wilson I. Gonsalves
Consulting or Advisory Role - Amgen (Inst)
 
Grzegorz S. Nowakowski
Consulting or Advisory Role - Celgene (Inst); Genentech (Inst); MorphoSys (Inst)
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst)
 
Eli Muchtar
No Relationships to Disclose
 
Rahma M. Warsame
No Relationships to Disclose
 
Robert A. Kyle
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Pfizer; Pharmacyclics
 
Shaji Kumar
Consulting or Advisory Role - Abbvie (Inst); Abbvie (Inst); Adaptive Biotechnologies; Amgen (Inst); Bluebird Bio (Inst); Celgene (Inst); Genecentrix; Genentech/Roche (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); Merck (Inst); Molecular Partners (Inst); Oncopeptides; Takeda (Inst)
Research Funding - Abbvie (Inst); CARsgen Therapeutics (Inst); Celgene (Inst); Janssen Oncology (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst); TeneoBio (Inst)
 
Prashant Kapoor
Honoraria - Cellectar; GlaxoSmithKline (Inst); Karyopharm Therapeutics; Pharmacyclics; Sanofi (Inst)
Consulting or Advisory Role - Sanofi (Inst)
Speakers' Bureau - Clinical Care Options
Research Funding - Abbvie (Inst); Amgen (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Sorrento Therapeutics (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Axis Pharma; GlaxoSmithKline; Janssen; Sanofi; Takeda